RxDoctor Payments DataLook up a doctor →

Sunil Sharma, MD

Family Medicine · Opelika, ALNPI 1376604272

Payments from drug & device makers

$17,339in general payments, 2019–2025

Across 1,040 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Pfizer$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Johnson & Johnson$840
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$17,326100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca105$2,324
GSK110$2,046
Pfizer110$1,615
AbbVie(2 entities)96$1,320
Novo Nordisk68$1,257
Johnson & Johnson61$840
Astellas Pharma US Inc40$659
Novartis42$594
Amarin Pharma, Inc.32$572
Boehringer Ingelheim45$539
Abbott33$474
Lilly USA, LLC33$429
Merck43$388
Bayer21$363
Amgen25$363
Otsuka America Pharmaceutical, Inc.13$279
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$243
Takeda Pharmaceuticals U.S.A., Inc.15$225
Corium, LLC12$224
Medtronic3$205
Xeris Pharmaceuticals, Inc.6$203
Ardelyx, Inc.9$190
Corcept Therapeutics8$166
Avanir Pharmaceuticals, Inc.3$155
Mylan Specialty L.p.7$139
Inspire Medical Systems, Inc.2$115
Sanofi-aventis U.S. LLC7$97
Lundbeck LLC5$85
Vanda Pharmaceuticals Inc.3$84
Shield Therapeutics Inc5$82
Exact Sciences5$81
Scilex Pharmaceuticals Inc.6$80
Daiichi Sankyo Inc.5$80
Phathom Pharmaceuticals, Inc.4$66
Esperion Therapeutics, Inc.4$62
Radius Health, Inc.2$53
Teva Pharmaceuticals USA, Inc.3$53
Adlon Therapeutics L.p.3$50
Baxter Healthcare2$45
Eisai Inc.3$38
Biohaven Pharmaceuticals, Inc.2$36
Supernus Pharmaceuticals, Inc.2$36
Antares Pharma, Inc.2$34
Currax Pharmaceuticals LLC2$29
Evoke Pharma, Inc.2$27
Kowa Pharmaceuticals America, Inc.2$25
Tris Pharma Inc1$24
Neurocrine Biosciences, Inc.1$21
Inogen, Inc.1$20
UCB, Inc.1$19
Hikma Pharmaceuticals USA1$19
Global Blood Therapeutics, Inc.1$19
Axsome Therapeutics, Inc.1$19
Idorsia Pharmaceuticals US Inc1$17
Sanofi Pasteur Inc.1$17
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$16
Otsuka Pharmaceutical Development & Commercialization, Inc.1$14
Biohaven Pharmaceutical Holding Company Ltd.1$14
Neurelis, Inc.1$14
Mannkind Corporation1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,339 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$311,846
Medicare patients
787
Services billed
5,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide225$251,529
OzempicSemaglutide193$219,764
EliquisApixaban273$169,420
JardianceEmpagliflozin163$128,505
FarxigaDapagliflozin Propanediol119$103,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter121$103,494
JanuviaSitagliptin Phosphate106$102,186
LinzessLinaclotide121$83,364
MyrbetriqMirabegron119$75,804
XareltoRivaroxaban99$68,786
Invega SustennaPaliperidone Palmitate12$44,393
FanaptIloperidone24$41,784
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$33,503
TrulicityDulaglutide40$33,348
XifaxanRifaximin11$30,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$429$284,877265 claims
Novo NordiskOzempic, Rybelsus$1,257$246,211213 claims
PfizerEliquis$1,615$169,420273 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$539$169,412228 claims
MerckJanuvia, Janumet$388$130,088143 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$2,046$128,371175 claims
Johnson & JohnsonXarelto, Invega Sustenna$840$113,179111 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,324$111,081131 claims
AbbVieLinzess$1,320$83,364121 claims
Astellas Pharma US IncMyrbetriq$659$75,804119 claims
Vanda Pharmaceuticals Inc.Fanapt$84$41,78424 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$243$30,62011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →